When Lifestyle Isn't Enough: The TRT Decision Framework

Key Takeaways

The previous article in this series ranked the natural levers by effect size and ended at a line: the man who has slept, lost the fat, corrected his deficiencies and still has symptoms with a persistently low number has moved past what lifestyle and supplements can do. This article is about what lies on the other side of that line.

It is deliberately not a guide to taking testosterone. It contains no doses, no formulations to prefer, and no product advice, because testosterone replacement therapy is a prescription treatment that requires a diagnosis, a baseline, and monitoring — and a man who starts it on the strength of a blog post has skipped all three. What it does contain is the evidence: what a diagnosis actually requires, what the large randomised trials found, what the risks are and how they are watched, and the one situation in which TRT is unambiguously the wrong tool.

What a Diagnosis Actually Requires

The 2018 Endocrine Society clinical practice guideline is explicit, and its diagnostic standard is stricter than most online testosterone clinics apply.

Both symptoms and a number. The guideline recommends making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone. A low number without symptoms is a laboratory finding. Symptoms without a low number are a differential diagnosis — and fatigue, low mood and poor concentration are produced by sleep deprivation in healthy men, as the sleep-restriction study showed.

Fasting, morning, twice. The initial test is a fasting morning total testosterone using an accurate assay, and the diagnosis is confirmed by repeating it. Testosterone has a circadian rhythm that peaks in the early morning, falls after eating, and varies day to day; an afternoon draw or a single result is not diagnostic. The TRAVERSE trial, for reference, required two fasting values below 300 ng/dL taken at least 48 hours apart.

Free testosterone when borderline. In men whose total testosterone is near the lower limit of normal, or who have a condition that alters SHBG — obesity, diabetes, thyroid disease, liver disease, ageing itself — the guideline recommends a free testosterone by equilibrium dialysis or an accurate calculated estimate. Total testosterone alone misclassifies men at both ends: a lean, high-SHBG man can have a normal total and a low free fraction; an obese, low-SHBG man can have a low total and adequate free testosterone.

Then find the cause. In men determined to have androgen deficiency, the guideline recommends further evaluation to establish why. The first branch is LH and FSH: elevated gonadotropins indicate primary hypogonadism (the testes are failing and the pituitary is shouting), while low or inappropriately normal gonadotropins indicate secondary hypogonadism (the signal is not being sent).

Secondary hypogonadism needs prolactin, a check for medication causes, iron studies, and — depending on severity and the prolactin result — pituitary imaging. A man in his thirties with a total testosterone in the low single figures and a suppressed LH does not have "low T"; he may have a pituitary tumour, and the difference is the entire point of the work-up.

Age-related decline versus disease

Testosterone falls about 1–2% a year from the thirties. That is not a disease, and the question of when age-related decline becomes a treatable condition was addressed directly by the European Male Ageing Study, a random population sample of 3,369 men aged 40–79 across eight centres with morning testosterone by mass spectrometry.

The findings drew a narrow box. Poor morning erection, low sexual desire and erectile dysfunction were the only symptoms with a syndromic relationship to testosterone; fatigue, depression and reduced physical vigour correlated but not syndromically. Late-onset hypogonadism was defined as at least three sexual symptoms plus total testosterone below 11 nmol/L (about 320 ng/dL) and free testosterone below 220 pmol/L. Most men with a mildly low reading and non-specific symptoms do not meet it.

What TRT Does — The Testosterone Trials

For decades, testosterone therapy in older men was prescribed on the basis of small trials and mechanism. The Testosterone Trials were the first adequately sized attempt to measure what it actually does: 790 men aged 65 or older, total testosterone below 275 ng/dL, symptoms suggesting hypoandrogenism, randomised to testosterone gel or placebo for one year, with each man enrolled in one or more of three trials.

Sexual function: a moderate benefit. Testosterone significantly increased sexual activity on the Psychosexual Daily Questionnaire (P < 0.001), along with sexual desire and erectile function.

Physical function: mixed. In the Physical Function Trial itself, the proportion of men improving their six-minute walk by at least 50 metres did not differ significantly between groups. Pooling all participants, it did: 20.5% on testosterone versus 12.6% on placebo (P = 0.003).

Vitality: no benefit. On the FACIT-Fatigue scale — the primary vitality endpoint — testosterone had no significant effect. Men on testosterone reported slightly better mood and lower depressive symptom severity.

The investigators' own summary: raising testosterone from moderately low to the mid-normal range for young men, for one year, had a moderate benefit for sexual function, some benefit for mood, and no benefit for vitality or walking distance. They also stated the sample was too small to draw conclusions about risk — which is why TRAVERSE was run.

That summary is worth holding against the marketing. The symptom most men cite when seeking TRT — low energy — is the one the largest efficacy trial did not improve.

What TRT Costs — Cardiovascular Safety in TRAVERSE

Concern that testosterone raised cardiovascular risk was never settled by the smaller trials, and a dedicated safety trial was needed. TRAVERSE enrolled 5,246 men aged 45–80 with pre-existing or high-risk cardiovascular disease, symptoms of hypogonadism, and two fasting testosterone levels below 300 ng/dL, randomised to daily transdermal testosterone gel (dose-adjusted to 350–750 ng/dL) or placebo. Mean treatment duration was 21.7 months; mean follow-up 33 months.

The primary result was reassuring. A major adverse cardiovascular event — cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke — occurred in 182 men (7.0%) on testosterone and 190 (7.3%) on placebo: hazard ratio 0.96, 95% CI 0.78–1.17, meeting the non-inferiority criterion (P < 0.001 for non-inferiority). Individual components and the secondary endpoint adding coronary revascularisation looked similar between groups.

The secondary signals were not. The testosterone group had a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism. None of these was the trial's primary question, and a secondary signal in a large trial is a hypothesis rather than a verdict — but pulmonary embolism sits on the same biological pathway as the erythrocytosis discussed below, and the guideline already lists thrombophilia as a reason not to start.

And bone went the wrong way. A pre-specified TRAVERSE subtrial followed 5,204 men for a median of 3.19 years for clinical fractures. Testosterone improves bone density, so fewer fractures were expected. Instead, fractures occurred in 91 men (3.50%) on testosterone versus 64 (2.46%) on placebo — hazard ratio 1.43, 95% CI 1.04–1.97 — and the incidence appeared higher on testosterone for every other fracture endpoint too. The authors could not explain it; increased activity in treated men is one speculation. It is a reminder that a surrogate marker moving in the right direction is not the same as the outcome doing so.

Non-inferiority for MACE is genuinely good news for men with a real diagnosis. It is not a clean bill of health, and it was demonstrated in men with two confirmed low readings and symptoms — not in men self-treating a borderline number.

The Monitoring That Comes With It

The guideline recommends a standardised monitoring plan during the first year: symptoms, adverse effects and compliance; serum testosterone; haematocrit; and prostate cancer risk. Each of those has a reason.

Erythrocytosis. Testosterone stimulates red cell production, and every formulation raises haematocrit. A network meta-analysis of 29 placebo-controlled trials in 3,393 men quantified the increase by route: gel +3.0 percentage points (95% CI 1.8–4.3), patch +1.4, oral testosterone undecanoate +4.3, intramuscular undecanoate +1.6, and intramuscular enanthate/cypionate +4.0 (2.9–5.1) — the short-acting injectables producing a significantly larger rise than the patch. The older 2010 meta-analysis of 51 studies found the same: haemoglobin up 0.80 g/dL and haematocrit up 3.18 percentage points on average. A haematocrit that climbs past the monitoring threshold is the most common reason to reduce or pause therapy, and it is the plausible mechanism behind the thromboembolic signal in TRAVERSE.

Prostate. The guideline recommends against starting testosterone in men with prostate cancer, a palpable nodule or induration, a PSA above 4 ng/mL, or a PSA above 3 ng/mL in men at increased risk without urological evaluation. The 2010 meta-analysis found no significant effect on prostate outcomes over the follow-up available, but that follow-up was short — three months to three years — and the guideline's monitoring of prostate risk in year one reflects the uncertainty rather than resolving it.

Sleep apnoea. Untreated severe obstructive sleep apnoea is a listed reason not to start, and testosterone can worsen it. Given that sleep fragmentation itself lowers testosterone, a man with symptoms of hypogonadism and untreated apnoea has a treatable cause of both.

Heart failure, recent events, thrombophilia. Uncontrolled heart failure, myocardial infarction or stroke within six months, and any thrombophilia are further listed contraindications in the guideline.

The list is long because the therapy works on the whole body. A testosterone clinic that does not measure haematocrit and PSA at baseline and during the first year is not following the guideline.

The Man Who Wants Children

This is the point at which the framework becomes absolute rather than probabilistic.

Sperm production requires intratesticular testosterone at concentrations far above those in the blood, and it is driven by LH and FSH from the pituitary. Exogenous testosterone raises the blood level and the pituitary responds by switching off — LH and FSH fall, intratesticular testosterone collapses, and spermatogenesis stops. This is reliable enough that testosterone was studied as a male contraceptive. A review of the literature from 1990–2013 concluded that most men recover normal sperm production within a year of stopping — which means some do not, and none do while on it.

The Endocrine Society guideline accordingly recommends against starting testosterone therapy in men planning fertility in the near term. Not "with caution." Against.

For a hypogonadal man who wants children, the conversation is a different one, and it belongs to a reproductive endocrinologist or andrologist. The options that maintain sperm production while raising testosterone — human chorionic gonadotropin, which mimics LH at the testis, and selective oestrogen receptor modulators such as clomiphene, which raise the pituitary's own output — are prescription therapies with their own monitoring. They are named here so that a man knows they exist and asks about them. No dose is given for either, and none should be taken from any non-clinical source.

What a man in this position can do without a prescription — the deficiency correction, the body-fat lever, and the spermatogenesis-support supplements with human data — is the Male Vitality Protocol, which is built specifically for the fertility outcome set rather than the hormone number.

The Decision Table

The middle column is where most men who search for TRT actually belong. The number is real; the cause is undetermined; and the cause changes both the treatment and the prognosis.

What This Framework Is Not

It is not a dosing guide. It names no formulation as preferable, no target level to aim for, no cycle, no adjunct. It does not tell anyone how to obtain testosterone, hCG or clomiphene, because those decisions require the examination, baseline bloods and follow-up that a prescriber provides and a website cannot.

It is also not an argument against TRT. For a man with a confirmed diagnosis, an identified cause, no contraindication and no fertility plans, testosterone therapy is guideline-recommended, its cardiovascular safety has been tested in the largest trial ever run on the question, and it produces a real if moderate benefit for the sexual symptoms that define the syndrome. The supplements reviewed in the previous article cannot match that, and pretending otherwise would be dishonest.

The framework exists because the population being prescribed testosterone has grown far faster than the population meeting the diagnostic criteria, and because the most common reason for a low reading in a man under 60 is something on the left-hand side of the table.

Frequently Asked Questions

My total testosterone was 350 ng/dL and I feel terrible. Is that hypogonadism?

Not on that alone. A single result, especially if not fasting and morning, is not diagnostic. Repeat it under the right conditions, add SHBG and a calculated free testosterone, and check LH and FSH. If it is confirmed and the symptoms are the sexual ones the EMAS study found to track testosterone, the conversation begins. If the symptoms are fatigue and low mood, sleep and body fat are the first suspects.

Does TRT cause heart attacks?

TRAVERSE — 5,246 men with cardiovascular risk, roughly three years of follow-up — found major adverse cardiac events non-inferior to placebo (7.0% vs 7.3%). It also found more atrial fibrillation, pulmonary embolism and acute kidney injury on testosterone. The honest summary is: not the heart attack risk that was feared, with other signals that warrant monitoring.

Will TRT give me more energy?

The Testosterone Trials measured this directly with a validated fatigue scale in men over 65 and found no significant benefit for vitality. Sexual function improved moderately; mood slightly. Energy is the promise most often made and least supported.

I want children in the next two years. Can I do a short course of TRT first?

The guideline recommends against starting testosterone in men planning fertility in the near term, because it suppresses sperm production and recovery after stopping takes months to a year and is not guaranteed. This is a conversation for a reproductive specialist, who may discuss hCG or clomiphene. Do not start testosterone.

Can supplements replace TRT once I have a diagnosis?

No. A 2024 systematic review of 52 booster trials found most fail to raise total testosterone at all, and the exceptions produce small effects. Confirmed hypogonadism with an identified cause is a medical condition. The natural levers are for the man on the left-hand side of the decision table, not the right.

What should be monitored once TRT starts?

Per the guideline: symptoms, adverse effects, serum testosterone, haematocrit, and prostate cancer risk during the first year. Haematocrit is the one most likely to force a change, because every formulation raises it.

Related Research

• Natural Testosterone Optimization: What Actually Works (and What Doesn't)
• The Male Vitality Protocol: Fertility and Sexual Function Beyond Testosterone
• The Male Vitality Protocol
• Tongkat Ali and Fadogia Agrestis: The Evidence-Based Guide to Natural TRT Support
• The Biohacker's Blood Panel: 40 Biomarkers